PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

• Katja Weisel,
• Vania Hungria,
• Hang Quach,
• Sung-Soo Yoon,
• Paula Rodríguez-Otero,
• Glenn Kroog,
• Arijit Sinha,
• Anita Boyapati,
• Charlotte Lyon,
• Karen Rodriguez Lorenc,
• Timothy Inocencio,
• James Harnett,
• Lei Chi,
• Vygngley Moore,
• Peter Voorhees

Affiliations

Katja Weisel

1 University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Vania Hungria

2 Clinica São Germano and Santa Casa Medical School, Department of Hematology, São Paulo, Brazil

Hang Quach

3 St. Vincent’s Hospital Melbourne, University of Melbourne, Melbourne, Australia

Sung-Soo Yoon

4 Seoul National University College of Medicine, Department of Internal Medicine, Seoul, Korea, Rep. of South

Paula Rodríguez-Otero

5 Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red Cáncer, Pamplona, Spain

Glenn Kroog

6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Arijit Sinha

7 Regeneron UK Ltd., Uxbridge, United Kingdom

Anita Boyapati

6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Charlotte Lyon

6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Karen Rodriguez Lorenc

6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Timothy Inocencio

6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

James Harnett

6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Lei Chi

6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Vygngley Moore

6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Peter Voorhees

8 Levine Cancer Institute, Charlotte, United States